本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

NRX Pharmaceuticals Inc.

2.75
+0.12004.56%
盘后2.65-0.0955-3.47%19:56 EDT
成交量:17.29万
成交额:46.28万
市值:6,536.72万
市盈率:-1.43
高:2.75
开:2.65
低:2.57
收:2.63
52周最高:6.01
52周最低:1.10
股本:2,376.99万
流通股本:1,641.89万
量比:0.42
换手率:1.05%
股息:- -
股息率:- -
每股收益(TTM):-1.9236
每股收益(LYR):-2.3605
净资产收益率:-682.61%
总资产收益率:-174.88%
市净率:-1.84
市盈率(LYR):-1.17

数据加载中...

2021/06/03

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/05/28

重要事件披露

8-K - Current report
2021/05/28

重要事件披露

8-K - Current report
2021/05/26

重要事件披露

8-K - Current report
2021/05/26

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/05/24

重要事件披露

8-K - Current report
2021/05/24

交易所摘牌声明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2021/05/24

交易所摘牌声明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2021/05/21

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2021/05/21

SEC问询函

CORRESP [Cover] - Correspondence
2021/05/21

SEC问询函

CORRESP [Cover] - Correspondence
2021/05/20

SEC问询函

CORRESP [Cover] - Correspondence
2021/05/14

[修订]年度报告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
2021/05/14

企业合并公告

425 - Prospectuses and communications, business combinations
2021/05/11

重要事件披露

8-K - Current report
2021/05/11

SEC问询函

CORRESP [Cover] - Correspondence
2021/04/29

重要事件披露

8-K - Current report
2021/04/21

重要事件披露

8-K - Current report
2021/04/19

重要事件披露

8-K - Current report
2021/04/19

企业合并公告

425 - Prospectuses and communications, business combinations